1Matthew J E, Andrew C, Baijit C et allet rozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB - 1 - and/or ErbB - 2 - Positive primary breast cancer [ J ]. Journal of Clinical Oneology, 2001,19(18) :3808 -3816.
2HenningM, Mikhall G, Yah Set al. Superior efficiency of letrozole versus tamoxlfen as first -line therapy for postmenopausal women with advanced breast cancer [ J]. Journal of Clinical Oncology,2001,19 ( 1 ) : 2596 - 2606.
3John RB, V assilis P. U palate on clinical rolo of tamoxifen [J]. Current Op - inion in Obstetrics and Gynecology, 2003, 15 (1) :13 -23.
4Morandi P, Rouzier R, Altundag K, et al. The role of aromatase inhibitots in the adjuvant treatment of breast carcinoma: the hi. D. Anderson Cancer Center evidence -based approach [ J] . Cancer, 2004, 101 (7) : 1482.
5Breast International Group. Letrozole vs Tamixifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer BIG1 -98 : Aprosoective randomized double - blind phaso Ⅲ study , 2005. 26.
6Goss P E, Ingle J N, Martino S, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early stage breast cancer [J]. N Engl J Med, 2003, 349:1793.
9Zwiefel K, Janni W. Current standards in the treatment of breast cancer[J] . Med Monatsschr Pharm, 2011, 34(8):280 -288.
10Obiorah I,Jordan VC. Maturitas. Progress in endocrine approach- es to the treatment and prevention of breast cancer [J]. Maturitas, 2011, 70(4):315 -321.
